File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Human pluripotent stem cell-derived cardiomyocytes for heart regeneration, drug discovery and disease modeling: From the genetic, epigenetic, and tissue modeling perspectives

TitleHuman pluripotent stem cell-derived cardiomyocytes for heart regeneration, drug discovery and disease modeling: From the genetic, epigenetic, and tissue modeling perspectives
Authors
Issue Date2013
Citation
Stem Cell Research and Therapy, 2013, v. 4 n. 4, p. article no. 97 How to Cite?
AbstractHeart diseases remain a major cause of mortality and morbidity worldwide. However, terminally differentiated human adult cardiomyocytes (CMs) possess a very limited innate ability to regenerate. Directed differentiation of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) into CMs has enabled clinicians and researchers to pursue the novel therapeutic paradigm of cell-based cardiac regeneration. In addition to tissue engineering and transplantation studies, the need for functional CMs has also prompted researchers to explore molecular pathways and develop strategies to improve the quality, purity and quantity of hESC-derived and iPSC-derived CMs. In this review, we describe various approaches in directed CM differentiation and driven maturation, and discuss potential limitations associated with hESCs and iPSCs, with an emphasis on the role of epigenetic regulation and chromatin remodeling, in the context of the potential and challenges of using hESC-CMs and iPSC-CMs for drug discovery and toxicity screening, disease modeling, and clinical applications. © 2013 BioMed Central Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/195152
ISSN
2015 Impact Factor: 4.504
2015 SCImago Journal Rankings: 1.405
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorChow, MZ-
dc.contributor.authorBoheler, KR-
dc.contributor.authorLi, RA-
dc.date.accessioned2014-02-25T01:40:14Z-
dc.date.available2014-02-25T01:40:14Z-
dc.date.issued2013-
dc.identifier.citationStem Cell Research and Therapy, 2013, v. 4 n. 4, p. article no. 97-
dc.identifier.issn1757-6512-
dc.identifier.urihttp://hdl.handle.net/10722/195152-
dc.description.abstractHeart diseases remain a major cause of mortality and morbidity worldwide. However, terminally differentiated human adult cardiomyocytes (CMs) possess a very limited innate ability to regenerate. Directed differentiation of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) into CMs has enabled clinicians and researchers to pursue the novel therapeutic paradigm of cell-based cardiac regeneration. In addition to tissue engineering and transplantation studies, the need for functional CMs has also prompted researchers to explore molecular pathways and develop strategies to improve the quality, purity and quantity of hESC-derived and iPSC-derived CMs. In this review, we describe various approaches in directed CM differentiation and driven maturation, and discuss potential limitations associated with hESCs and iPSCs, with an emphasis on the role of epigenetic regulation and chromatin remodeling, in the context of the potential and challenges of using hESC-CMs and iPSC-CMs for drug discovery and toxicity screening, disease modeling, and clinical applications. © 2013 BioMed Central Ltd.-
dc.languageeng-
dc.relation.ispartofStem Cell Research and Therapy-
dc.titleHuman pluripotent stem cell-derived cardiomyocytes for heart regeneration, drug discovery and disease modeling: From the genetic, epigenetic, and tissue modeling perspectives-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1186/scrt308-
dc.identifier.pmid23953772-
dc.identifier.pmcidPMC3854712-
dc.identifier.scopuseid_2-s2.0-84887940374-
dc.identifier.hkuros222586-
dc.identifier.hkuros219961-
dc.identifier.volume4-
dc.identifier.issue4-
dc.identifier.spagearticle no. 97-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats